Christopher Darke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christopher Darke has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
J. Street
Welsh Transplantation and Immunogenetics, Laboratory Welsh Blood Service, Pontyclun, Wales, UK
35 shared publicationsJ. Johnson
Welsh Transplantation and Immunogenetics Laboratory Welsh Blood Service Wales UK
18 shared publicationsL. Hammond
New Zealand Blood Service, Auckland, New Zealand
11 shared publicationsJ. Pepperall
Welsh Transplantation and Immunogenetics Laboratory; Welsh Blood Service; Pontyclun Wales UK
10 shared publicationsC. Harvey
Welsh Transplantation and Immunogenetics Laboratory, Welsh Blood Service, Wales, UK
9 shared publicationsJ. Downing
Welsh Transplantation and Immunogenetics Laboratory, Welsh Blood Service, Pontyclun, Wales, UK
7 shared publications
Latest Publications
- Open Access
- 1 October 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (10) , 595-601
HLA gene and haplotype frequencies in a Nagaybaks population from the Chelyabinsk Region (Russian South Urals)
- 1 October 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (10) , 595-601
Open AccessHLA gene and haplotype frequencies in a Nagaybaks population from the Chelyabinsk Region (Russian South Urals)
- 10 July 2017
- Published by Wiley in International Journal of Immunogenetics
- Vol. 44 (5) , 225-233
Epitopes and motifs of theHLA‐B*14 allele family products and relatedHLA‐B14 cross‐reactive specificities
Summary: The split specificities ofHLA‐B14 (B64, B65) are assigned to the B*14:01 (B64) and B*14:02 (B65) products only. Of the further 50 B*14 expressed products, only B*14:03 and B*14:06 are officially designated asHLA‐B14. The B*14:08 product differs from B64 by a single amino acid substitution of W97R, while the B*14:53 specificity (which is a “short” B14 and neither B64 nor B65) differs from B64 by three residues (W97S, Y113H and F116Y). Comprehensive testing of B*14:08:01 cells (using 49 alloantisera with B64 or B64, B65 specificities, and five monoclonal antibodies with B65 or B64, B65 activity) showed that the B*14:08 specificity is, like the B*14:53 product, neither B64 nor B65 and appears as a “short” B14 specificity. To help understand the serological reactivity of the B*14:08 and B*14:53 products, and B64 and B65, we identified seven published epitopes (11AV, 97W, 61ICT, 116F, 131S+163T, 170RHand 420) and, by inspection, 29 motifs, that encompass one or more of B64, B65 and variousHLA‐B14 cross‐reactive group specificities. We then considered the possession of these epitopes and motifs by the products of B*14:01 to B*14:06, B*14:08 and B*14:53. Seventeen of the 29 motifs fully complied with the one‐/two‐patch functional epitope concept for amino acid proximity, as determined by Cn3D software, the remainder partially complied. The nature and patterns of epitopes and motifs possessed by both B*14:08 and B*14:53 specificities supported their designation asHLA‐B14 but non‐B64/B65. Also that epitope 97W, with 11S or 11A, is critical for serological B64 and B65 reactivity. And conversely, that epitope 116F, and several identified motifs, are probably unimportant forHLA‐B14 antibody reactivity. The previous submission that the B*14:03 specificity isHLA‐B65 was compatible with its epitope/motif pattern. B*14:04 cells would also be expected to react as B65, based on its epitope/motif pattern, and not as B64 as previously implied. Also, from their epitope/motif patterns, and external serological information, it is probable that the B*14:05 and B*14:06 specificities will both appear as “short”HLA‐B14, non‐B64/B65. Several epitopes and motifs encompassed a range ofHLA‐B specificities included in the serologicalHLA‐B14 cross‐reactive group, thus supporting these original serological findings.
- 10 July 2017
- Published by Wiley in International Journal of Immunogenetics
- Vol. 44 (5) , 225-233
Epitopes and motifs of theHLA‐B*14 allele family products and relatedHLA‐B14 cross‐reactive specificities
Summary: The split specificities ofHLA‐B14 (B64, B65) are assigned to the B*14:01 (B64) and B*14:02 (B65) products only. Of the further 50 B*14 expressed products, only B*14:03 and B*14:06 are officially designated asHLA‐B14. The B*14:08 product differs from B64 by a single amino acid substitution of W97R, while the B*14:53 specificity (which is a “short” B14 and neither B64 nor B65) differs from B64 by three residues (W97S, Y113H and F116Y). Comprehensive testing of B*14:08:01 cells (using 49 alloantisera with B64 or B64, B65 specificities, and five monoclonal antibodies with B65 or B64, B65 activity) showed that the B*14:08 specificity is, like the B*14:53 product, neither B64 nor B65 and appears as a “short” B14 specificity. To help understand the serological reactivity of the B*14:08 and B*14:53 products, and B64 and B65, we identified seven published epitopes (11AV, 97W, 61ICT, 116F, 131S+163T, 170RHand 420) and, by inspection, 29 motifs, that encompass one or more of B64, B65 and variousHLA‐B14 cross‐reactive group specificities. We then considered the possession of these epitopes and motifs by the products of B*14:01 to B*14:06, B*14:08 and B*14:53. Seventeen of the 29 motifs fully complied with the one‐/two‐patch functional epitope concept for amino acid proximity, as determined by Cn3D software, the remainder partially complied. The nature and patterns of epitopes and motifs possessed by both B*14:08 and B*14:53 specificities supported their designation asHLA‐B14 but non‐B64/B65. Also that epitope 97W, with 11S or 11A, is critical for serological B64 and B65 reactivity. And conversely, that epitope 116F, and several identified motifs, are probably unimportant forHLA‐B14 antibody reactivity. The previous submission that the B*14:03 specificity isHLA‐B65 was compatible with its epitope/motif pattern. B*14:04 cells would also be expected to react as B65, based on its epitope/motif pattern, and not as B64 as previously implied. Also, from their epitope/motif patterns, and external serological information, it is probable that the B*14:05 and B*14:06 specificities will both appear as “short”HLA‐B14, non‐B64/B65. Several epitopes and motifs encompassed a range ofHLA‐B specificities included in the serologicalHLA‐B14 cross‐reactive group, thus supporting these original serological findings.
- 21 June 2017
- Published by Wiley in International Journal of Immunogenetics
- Vol. 44 (4) , 169-170
The HLA‐C*05 family allele – C*05:142
Summary: The sequencing of exons 2–7 of a likely new HLA‐C*05 allele identified the second example of HLA‐C*05:142, in a male UK European, within a few months of the first example being found in Germany. C*05:142 differs from C*05:01:01:01 by a single base (395G>C) in exon 3 resulting in an amino acid substitution of R108P. Comprehensive serological HLA‐Cw5 typing, using 19 antisera, indicated that C*05:142 encodes a “normal” Cw5 specificity. Failure to identify the involvement of position 108 in published HLA‐C epitopes supported this assertion. The likely HLA class I C*05:142‐bearing haplotype is A*02:01~C*05:142~B*44:02. This new allele has a maximum frequency of 0.00001, in 34,743 sequenced‐based typed subjects, contrasting with that of C*05:01 (allele frequency 0.10441), in our local, largely UK European, blood donors.
- 21 June 2017
- Published by Wiley in International Journal of Immunogenetics
- Vol. 44 (4) , 169-170
The HLA‐C*05 family allele – C*05:142
Summary: The sequencing of exons 2–7 of a likely new HLA‐C*05 allele identified the second example of HLA‐C*05:142, in a male UK European, within a few months of the first example being found in Germany. C*05:142 differs from C*05:01:01:01 by a single base (395G>C) in exon 3 resulting in an amino acid substitution of R108P. Comprehensive serological HLA‐Cw5 typing, using 19 antisera, indicated that C*05:142 encodes a “normal” Cw5 specificity. Failure to identify the involvement of position 108 in published HLA‐C epitopes supported this assertion. The likely HLA class I C*05:142‐bearing haplotype is A*02:01~C*05:142~B*44:02. This new allele has a maximum frequency of 0.00001, in 34,743 sequenced‐based typed subjects, contrasting with that of C*05:01 (allele frequency 0.10441), in our local, largely UK European, blood donors.
HLA‐A*24:374—A novel allele encoding the HLA‐A2403 specificity
HLA‐A*24:374 differs from A*24:03:01:01 by 2 exon 3 bases resulting in a substitution of T163E.
HLA‐A*24:374—A novel allele encoding the HLA‐A2403 specificity
HLA‐A*24:374 differs from A*24:03:01:01 by 2 exon 3 bases resulting in a substitution of T163E.
Three new HLA alleles—B*49:43, C*03:321 and DQB1*02:72
Immunogenetic information is provided on 3 novel HLA‐B, ‐C and ‐DQB1 alleles.
Three new HLA alleles—B*49:43, C*03:321 and DQB1*02:72
Immunogenetic information is provided on 3 novel HLA‐B, ‐C and ‐DQB1 alleles.
Five new HLA alleles with synonymous mutations: A*01:01:65, A*01:01:66, B*44:03:35, DRB1*15:01:30 and DQB1*02:01:24
Immunogenetic information is provided on five novel alleles with synonymous mutations.
Five new HLA alleles with synonymous mutations: A*01:01:65, A*01:01:66, B*44:03:35, DRB1*15:01:30 and DQB1*02:01:24
Immunogenetic information is provided on five novel alleles with synonymous mutations.
A further HLA‐DRB1*15 family allele – DRB1*15:112
HLA‐DRB1*15:112 differs from DRB1*15:01:01:01 by one base (282G > T) in exon 2 resulting in K65N.
A further HLA‐DRB1*15 family allele – DRB1*15:112
HLA‐DRB1*15:112 differs from DRB1*15:01:01:01 by one base (282G > T) in exon 2 resulting in K65N.
- 16 June 2016
- Published by Wiley in International Journal of Immunogenetics
- Vol. 43 (4) , 236-239
A novelHLA‐B*14 allele – B*14:53 – genetics and serology
Summary: HLA‐B*14:53 was found in aUKEuropean normal blood donor prior to registration on the Welsh Bone Marrow Donor Registry. It differs from B*14:13 by one base (103G>T) in exon 2 resulting in a substitution of alanine (A) in B*14:13 to serine (S) in B*14:53. Unique among currentHLA‐B*14 alleles, B*14:53 and B*14:13 share a motif of 59 bases between positions 361 and 419 in exon 3. This motif is present in numerousHLA‐B alleles the commonest overall being B*08:01, suggesting that both B*14:53 and B*14:13 arose from intralocus gene conversion events with B*08:01. Thus, B*14:53 probably arose from B*14:01:01 (which hasTCCat codon 11 (S), while B*14:13 arose from B*14:02:01:01 which has GCC at codon 11 (A). Additionally, the two likely B*14:53‐bearing and B*14:13‐bearing haplotypes are typical of B*14:01:01‐bearing and B*14:02:01:01‐bearing haplotypes, respectively. Serological testing, using 49 antisera withHLA‐B64, or B64, B65 reactivity, showed that the B*14:53 specificity did not react as a B64 (B*14:01) specificity and may appear as a short/weakHLA‐B14. This implies that residues additional to S at position 11 are involved inHLA‐B64 serological identity; for example, the motif 11S 97W 116F is possessed by B*14:01 and many other B*14 products (and B*39:79 plus someHLA‐C products) but not B65 (B*14:02) or the B*14:53 specificity. B*14:53 was found in a randomHLAsequence‐based typed population of 32 530 normal subjects indicating a low precision allele frequency of 0.000015 in subjects resident in Wales.
- 16 June 2016
- Published by Wiley in International Journal of Immunogenetics
- Vol. 43 (4) , 236-239
A novelHLA‐B*14 allele – B*14:53 – genetics and serology
Summary: HLA‐B*14:53 was found in aUKEuropean normal blood donor prior to registration on the Welsh Bone Marrow Donor Registry. It differs from B*14:13 by one base (103G>T) in exon 2 resulting in a substitution of alanine (A) in B*14:13 to serine (S) in B*14:53. Unique among currentHLA‐B*14 alleles, B*14:53 and B*14:13 share a motif of 59 bases between positions 361 and 419 in exon 3. This motif is present in numerousHLA‐B alleles the commonest overall being B*08:01, suggesting that both B*14:53 and B*14:13 arose from intralocus gene conversion events with B*08:01. Thus, B*14:53 probably arose from B*14:01:01 (which hasTCCat codon 11 (S), while B*14:13 arose from B*14:02:01:01 which has GCC at codon 11 (A). Additionally, the two likely B*14:53‐bearing and B*14:13‐bearing haplotypes are typical of B*14:01:01‐bearing and B*14:02:01:01‐bearing haplotypes, respectively. Serological testing, using 49 antisera withHLA‐B64, or B64, B65 reactivity, showed that the B*14:53 specificity did not react as a B64 (B*14:01) specificity and may appear as a short/weakHLA‐B14. This implies that residues additional to S at position 11 are involved inHLA‐B64 serological identity; for example, the motif 11S 97W 116F is possessed by B*14:01 and many other B*14 products (and B*39:79 plus someHLA‐C products) but not B65 (B*14:02) or the B*14:53 specificity. B*14:53 was found in a randomHLAsequence‐based typed population of 32 530 normal subjects indicating a low precision allele frequency of 0.000015 in subjects resident in Wales.
- 18 December 2015
- Published by Wiley in International Journal of Immunogenetics
- Vol. 43 (1) , 40-44
Immunogenetics of three novel HLA‐Class II alleles: DRB1*03:112, DQB1*03:02:16 and DQB1*03:139
Summary: Three novel HLA‐Class II alleles, DRB1*03:112, DQB1*03:02:16 and DQB1*03:139, are described with predicted bearing haplotypes of A*02:01, B*40:01, C*03:04, DRB1*03:112, DQB1*02:01; A*23:01, B*15:01, C*03:03, DRB1*04:01, DQB1*03:02:16 and A*01:01, B*44:02, C*05:01/03, DRB1*04:01, DQB1*03:139. Serological tests showed that the DRB1*03:112 and DQB1*03:139 specificities failed to react as expected with some well‐documented monoclonal antibodies. Subsequent examination of published HLA‐Class II epitopes and inspection of amino acid motifs suggested that epitopes exist that include the positions of their single substitutions (F31C between DRB1*03:01:01:01 and DRB1*03:112, and R48P between DQB1*03:01:01:01 and DQB1*03:139 specificities). This suggests that the reactivity of the monoclonal antibodies used was dependent on these epitopes and that their loss from these rare allele products resulted in their aberrant serology. The new alleles were found after the sequence‐based typing of 32 530 random UK European routine blood donors suggesting that each has a maximum carriage frequency of 0.0031% in the blood donor population resident in Wales.
- 18 December 2015
- Published by Wiley in International Journal of Immunogenetics
- Vol. 43 (1) , 40-44
Immunogenetics of three novel HLA‐Class II alleles: DRB1*03:112, DQB1*03:02:16 and DQB1*03:139
Summary: Three novel HLA‐Class II alleles, DRB1*03:112, DQB1*03:02:16 and DQB1*03:139, are described with predicted bearing haplotypes of A*02:01, B*40:01, C*03:04, DRB1*03:112, DQB1*02:01; A*23:01, B*15:01, C*03:03, DRB1*04:01, DQB1*03:02:16 and A*01:01, B*44:02, C*05:01/03, DRB1*04:01, DQB1*03:139. Serological tests showed that the DRB1*03:112 and DQB1*03:139 specificities failed to react as expected with some well‐documented monoclonal antibodies. Subsequent examination of published HLA‐Class II epitopes and inspection of amino acid motifs suggested that epitopes exist that include the positions of their single substitutions (F31C between DRB1*03:01:01:01 and DRB1*03:112, and R48P between DQB1*03:01:01:01 and DQB1*03:139 specificities). This suggests that the reactivity of the monoclonal antibodies used was dependent on these epitopes and that their loss from these rare allele products resulted in their aberrant serology. The new alleles were found after the sequence‐based typing of 32 530 random UK European routine blood donors suggesting that each has a maximum carriage frequency of 0.0031% in the blood donor population resident in Wales.